Compare Quest Diagnostics Inc (DGX) vs iShares MSCI United Kingdom (FTSE) (EWU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs iShares MSCI United Kingdom (FTSE) — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while iShares MSCI United Kingdom (FTSE) trades at $46.31. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while iShares MSCI United Kingdom (FTSE) pays none. Which is the better fit depends on your goals.
| DGX | EWU | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $216.02 | $48.68 |
52-Week Low | $166.42 | $39.59 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
EWU, the iShares MSCI United Kingdom ETF, trades at $46.36, down 0.52% on the day, with technical indicators showing a neutral to bearish bias. The ETF's performance is heavily influenced by UK economic conditions and political developments, including recent leadership changes. Key holdings in financials, consumer staples, and healthcare drive its NAV, with the top 10 holdings comprising over half of the portfolio.
Outlook remains cautious due to UK political instability and economic headwinds, though potential exists from M&A activity and valuation discounts. Risks include sterling volatility and fiscal constraints. Analyst sentiment is mixed, reflecting uncertainty over near-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →
